Proactive Research analyst Emma Ulker discusses 's () 2019 business update and subsequent licence agreement for Feraccru/Accrufer with the integrated specialty pharma company Beijing Aosaikang Pharmaceutical Co Ltd (ASK Pharm) which covers China, Hong Kong, Macau and Taiwan.
Ulker adds that a key highlight of 2019 included presentation of positive data from STX’s AEGIS head-to-head study of Feraccru vs the leading IV iron, Ferinject.
Click here to read Emma's note on Shield Therapeutics achieving significant milestones
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE